CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-07-07): Experts find rogue stem cells in liver cancer

Science

Experts find rogue stem cells in liver cancer

Last Updated: 2011-07-07 12:41:17 -0400 (Reuters Health)

HONG KONG (Reuters) - Liver cancers are embedded with a type of super cancer stem cells that make them resistant to chemotherapy, spread to other body parts and stage a comeback even after they are surgically removed, researchers in Hong Kong reported on Thursday.

The discovery, scheduled for publication this week in the journal Cell Stem Cell, is important because it means experts can target these stem cells in their fight against liver cancer.

These cancer stem cells bear the surface protein CD24, and patients with high counts of CD24 tend to have poorer chances of survival, said lead researcher Irene Ng, pathology professor and director of the State Key Laboratory for Liver Research at the University of Hong Kong.

"CD24 is like a button, a switch on some cancer stem cells. Once they are switched on, they activate a protein in the cell called STAT3," Ng told a news conference.

Her colleague Terence Lee said: "STAT3 goes into the nucleus of the cells and carries out its functions, which are to form tumors, spread and be drug resistant. If we inhibit the function of STAT3, we block the function of cancer stem cells."

In a murine model, Ng and colleagues found that liver cancer enriched with CD24 cancer stem cells was resistant to chemotherapy.

The researchers then injected two colonies of liver cancer cells - one with CD24 stem cells and the other without - into separate parts of the liver of the same mouse.

"That part of the liver with CD24 cancer stem cells grew cancer and the cancer spread to the lungs. But not the other part of the liver without CD24 cancer stem cells," Lee said.

They went back to human liver cancer patients and found that those with high concentrations of CD24 had a 67% chance of cancer recurrence in the first year after surgery, compared to 21% recurrence in those with low CD24 count.

Those with a high CD24 count had an 80% chance of their cancer spreading, compared to 32% in patients with a low CD24 count.

Ten percent of China's population carries the hepatitis B virus, a key cause of liver cancer. There are 500,000 new cases of liver cancer worldwide a year, over 50 percent in China.

SOURCE: http://bit.ly/4kkpZ6

Cell Stem Cell 2011.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.